This was a dose-escalation study; therefore, the maximum tolerated dose of albumin was established. Tolerability was based on the rate of severe-to-life-threatening heart failure and anaphylactic reaction. Also, functional outcome at 3 months was assessed. This evidence concerns the gene ALB and heart failure.